Expert Systems in Renal Disease Kent Renal ServiceUniversity of KentSalford Hospital Chris Farmer Bernhard Klebe Jean IrvingDonal O’Donoghue Paul StevensRoger.

Slides:



Advertisements
Similar presentations
Streatham & Clapham Health Renal Outreach Clinic
Advertisements

Chronic kidney disease
Chronic kidney disease
CKD ML/LH What are people hoping to cover from the session today?
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
Risk Group no RF or RF coded 18 Numerator 1 Patient not at risk.
National Diabetes Audit (NDA) PARTNERSHIP WORKING WITH PATIENTS AND SERVICE USERS Laura Fargher Diabetes UK.
Slides courtesy of Matt Hall Nottingham University Hospitals February 2011 Slides courtesy of Matt Hall Nottingham University Hospitals February 2011 Slides.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
18 week commissioning pathways for kidney disease and renal transplantation Specialty Clinical Leads Lawrence Goldberg: CKD and ESRF pathways John Scoble:
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.
Primary care of hypertensive patients and the risk of acute events Irina Stirbu-Wagner Markus MJ Nielen Maaike Langelaan Robert A. Verheij Joke C. Korevaar.
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Improving Data Recording in Primary Care Data Michelle Page & Hassy Dattani THIN.
Lesley Stevens MD Tufts-New England Medical Center
Azara Proprietary & Confidential Controlling High Blood Pressure 2014 Measure Changes Improving Patient Outcomes through Data.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
The extent of albuminuria in individuals with diabetes within Heart of Birmingham PCT Mark Jesky Research Registrar.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
CGS BILLING SERVICE
RENAL DISEASE IN DIABETES
Implementing NICE guidance
Risk estimation and the prevention of cardiovascular disease SIGN 97.
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients
Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
The 2009 New Zealand Cardiovascular Guidelines Handbook What’s new?
The management of renal problems in primary care Hugh Gallagher Consultant Nephrologist St Helier Hospital.
Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients
Section 5: Configuration of healthcare to manage CKD.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
UK Renal Registry 9 th Annual Report 2006 Fig 11.1 UK transplantation prevalence rate per million population by age and gender on 31/12/2005.
Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients
The National CKD Audit and Quality Improvement Programme for CKD in Primary Care The project will be advised by key stakeholders, including: From BMJ Informatica,
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr. Goh Bak Leong Expert Panel: Dato’ Dr. Zaki Morad b Mohd Zaher (Chair) Dr. Goh Bak Leong (Co-Chair) Dr. Fan.
“Do Once and Share” Feedback from the Renal Team B Stribling, K Harris, A Keogh, J Medcalf.
Section IV. Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension 2015 Canadian Hypertension Education Program Recommendations.
Project supported by A Package of Innovation for Managing kidney disease in primary care Registered Office: Nene Hall, Lynch Wood Park, Peterborough PE2.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Introduction to Disease Prevalence modelling Day 6 23 rd September 2009 James Hollinshead Paul Fryers Ben Kearns.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ صدق الله العظيم.
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Decline in Estimated Glomerular Filtration Rate and.
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Section 6: Management in primary care
Diabetes Clinical Audit- July/Aug 2014
Hypertension November 2016
NDA – THE LATEST DATA Prof Roger Gadsby MBE FRCGP Honorary Associate Clinical Professor , WMS GP Clinical Lead National Diabetes Audit.
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
Introduction Methods Results Conclusions References
Dr Paul Stevens Consultant Nephrologist East Kent Hospitals NHS Trust
Copyright © 2012 American Medical Association. All rights reserved.
The percentage of subjects with de novo development of renal function impairment (GFR
MANAGING KIDNEY DISEASE IN PRIMARY CARE
Prehypertension and chronic kidney disease: the ox or the plow?
Section 5: Configuration of healthcare to manage CKD
Hypertension November 2016
Hypertension Implementing NICE guidance 2 nd Edition March 2013 NICE clinical guideline 127.
UK Renal Registry 10th Annual Report 2007
Consultant Clinical Biochemist
Presentation transcript:

Expert Systems in Renal Disease Kent Renal ServiceUniversity of KentSalford Hospital Chris Farmer Bernhard Klebe Jean IrvingDonal O’Donoghue Paul StevensRoger CooleyRachel Middleton Helen Hobbs

Referral Variance SD Referral variance Corrected for age, gender, ethnicity and population Extremal Quotient Farmer C, Hobbs H, Klebe B, Stevens P

Referral Rates

Proportion of Referrals Seen Percentage

Outpatient Activity 623 forms assessed 623 forms assessed 53.2% Male 53.2% Male Median Age 59 (16-93) Median Age 59 (16-93) Median SCr 124  mol/L (35-832) Median SCr 124  mol/L (35-832) Median calculated GFR 50.4 (4.7>90) ml/min Median calculated GFR 50.4 (4.7>90) ml/min John RI, Farmer CK, Abbs I, Stevens PE

Intervention in the Last Year * * Denotes number of biopsies performed ever

Possible to identify patients who could be discharged based on: Possible to identify patients who could be discharged based on: Stable Chronic Kidney Disease Blood Pressure under 140/85 No alteration in treatment in the past year 29.8% of patients followed up

Possible to identify patients who could be discharged based on: Possible to identify patients who could be discharged based on: Stable Chronic Kidney Disease Blood Pressure under 140/85 No alteration in treatment in the past year 29.8% of patients followed up Provided there is a robust follow up arrangement

UK Referral Guidelines NEOERICA Per Million Action Stage Other Tests Stable Refer Hb< Refer BP >130/90 On 3 agents Refer GFR falling Stage Another test then refer 960Refer Stage 5 536Refer

UK Referral Guidelines NEOERICA Per Million Action Stage Other Tests Stable Refer Hb< Refer BP >130/90 On 3 agents Refer GFR falling Stage Another test then refer 960Refer Stage 5 536Refer 2558

Referral Rates

Referral Rates

ARF Stage 5 Stage 4 Unstable 3 Immunosuppressed Stage 4 (stable) Hypertension Stable Stage 3 Stage 1 or 2 At Risk Populations Intensive Management Hospital Based Care Community based care Increasing Level Of Care Needed Structured delivery of care

Expert System in Kidney Disease Identify patients requiring intensive management Identify patients requiring intensive management Facilitate robust follow up of patients discharged from hospital based care Facilitate robust follow up of patients discharged from hospital based care Provide patient specific guidance for further investigations of patients with CKD Provide patient specific guidance for further investigations of patients with CKD Manage stable chronic kidney disease in the community Manage stable chronic kidney disease in the community

General Practice Database Systems Data Extraction MIQUEST Database Reporting Tool Complete Database Study Data Patient Reports Decision Support Expert System

General Practice Database Systems Data Extraction MIQUEST Database Reporting Tool Complete Database Study Data Patient Reports Decision Support Expert System

General Practice Database Systems Data Extraction MIQUEST Database Reporting Tool Complete Database Study Data Patient Reports Decision Support Expert System

General Practice Database Systems Data Extraction MIQUEST Database Reporting Tool Complete Database Study Data Patient Reports Decision Support Expert System

Patient id varchar (20) pracid int sex varchar(6) dob date gp varchar(8) regDate date Creatinine id varchar (20) date date value int pracid int ReportedGfr id varchar (20) date date value float pracid int Bp id varchar (20) date date systolic int diastolic int pracid int Calcium id varchar (20) date date value float pracid int Hb id varchar (20) date date value float pracid int Phosphate id varchar (20) date date value float pracid int Potassium id varchar (20) date date value float pracid int Pth id varchar (20) date date value int pracid int Known id varchar (20) code varchar(30) date date pracid int Tables are linked by id and pracid to patient table. Tables created by SetupDatabase and filled by MiqReader. Result id varchar (20) date date stage int exitno int pracid int FurtherAction id varchar (20) date date actionid int pracid int done boolean Recommendations exitNo int recommendation varchar(500) Actions actionid int action varchar(30) Practice pracid int name varchar(30) KnownRubric code varchar(30) rubric varchar(30) Treatment id varchar (20) code varchar(30) date date pracid int type int Drug code varchar(30) rubric varchar(200) Category type int category varchar(30) Population pracid int population int date date Gfr id varchar (20) date date value float pracid int (may decide not to keep this – recalculable) Diabetic id varchar (20) code varchar(30) date date pracid int DiabeticRubric code varchar(30) rubric varchar(30) Glucose id varchar (20) date date value int pracid int HbA1c id varchar (20) date date value int pracid int Cholesterol id varchar (20) Code date date value int pracid int Proteinuria id varchar (20) Code date date value int pracid int Triglyceride id varchar (20) date date value int pracid int PCR id varchar (20) date date value int pracid int Proteinuria id varchar (20) Code date date value int pracid int GPDecision id varchar (20) date date pracid int decisionCode int Decisions decisionCode int rubric varchar(30) B12 id varchar (20) Code date date value int pracid int Referral id varchar (20) code varchar(30) date date referralType int pracid int Initially to indicate clinic attendance

General Practice Database Systems Data Extraction MIQUEST Database Reporting Tool Complete Database Study Data Patient Reports Decision Support Expert System

Development Recruitment of GP Surgeries Recruitment of GP Surgeries 8 Practices 8 Practices 100,000 people registered with their GP 100,000 people registered with their GP Development of decision support tool and secondary checking of outputs Development of decision support tool and secondary checking of outputs Development of “expert” areas such as rate of decline of renal function Development of “expert” areas such as rate of decline of renal function Implementation and checking in a second UK region Implementation and checking in a second UK region Cluster randomised controlled trial Cluster randomised controlled trial